Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion

被引：26
|
作者：
Lorillon, Gwenael [1 ]
Jouenne, Fanelie [1 ,2 ]
Baroudjian, Barouyr [1 ]
de Margerie-Mellon, Constance [1 ,2 ]
Vercellino, Laetitia [1 ]
Meignin, Veronique [1 ,3 ]
Lebbe, Celeste [1 ,2 ,4 ]
Vassallo, Robert [5 ]
Mourah, Samia [1 ,2 ,4 ]
Tazi, Abdellatif [1 ,2 ,6 ]
机构：
[1] AP HP, Paris, France
[2] Univ Paris Diderot, Paris, France
[3] INSERM, UMR S1165, Paris, France
[4] INSERM, U976, Paris, France
[5] Mayo Clin, Rochester, MN USA
[6] CRESS, U1153, Paris, France
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 198卷 / 05期
关键词：
ERDHEIM-CHESTER DISEASE; MUTATIONS; VEMURAFENIB; ACTIVATION;
D O I：
10.1164/rccm.201802-0275LE
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：675 / 678
页数：4
相关论文
共 50 条
  • [21] Clinical Study of Map2K1-Mutated Langerhans cell Histiocytosis in Children
    Yang, Ying
    Wang, Chanjuan
    Wang, Dong
    Cui, Lei
    Li, Na
    Lian, Hongyun
    Ma, Honghao
    Zhao, Yunze
    Zhang, Liping
    Liu, Wei
    Wang, Yizhuo
    Wu, Wanshui
    Zhang, Rui
    Li, Zhigang
    Wang, Tianyou
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S28 - S28
  • [22] Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children
    Yang, Ying
    Wang, Chanjuan
    Wang, Dong
    Cui, Lei
    Li, Na
    Lian, Hongyun
    Ma, Honghao
    Zhao, Yunze
    Zhang, Liping
    Liu, Wei
    Wang, Yizhuo
    Wu, Wanshui
    Zhang, Rui
    Li, Zhigang
    Wang, Tianyou
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (09) : 2517 - 2527
  • [23] Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia
    Andritsos, Leslie A.
    Anghelina, Mirela
    Grieselhuber, Nicole R.
    Roychowdhury, Sameek
    Reeser, Julie
    Timmers, Cynthia
    Freud, Aharon G.
    Blachly, James S.
    Lucas, David M.
    Lozanski, Gerard
    Jones, Jeffrey
    Rogers, Kerry A.
    Zhao, Weiqiang
    Grever, Michael R.
    BLOOD, 2016, 128 (22)
  • [24] A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children
    Wang, Leyuan
    Yuan, Lin
    Du, Xizi
    Zhou, Kai
    Yang, Yu
    Qin, Qingwu
    Yang, Liangchun
    Xiang, Yang
    Qu, Xiangping
    Liu, Huijun
    Qin, Xiaoqun
    Liu, Chi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib
    Kumamoto, Tadashi
    Aoki, Yuki
    Sonoda, Tomoko
    Yamanishi, Miho
    Arakawa, Ayumu
    Sugiyama, Masanaka
    Shirakawa, Nami
    Ishimaru, Sae
    Saito, Yoshimasa
    Maeshima, Akiko
    Maeda, Miho
    Ogawa, Chitose
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (02) : 228 - 232
  • [26] A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib
    Tadashi Kumamoto
    Yuki Aoki
    Tomoko Sonoda
    Miho Yamanishi
    Ayumu Arakawa
    Masanaka Sugiyama
    Nami Shirakawa
    Sae Ishimaru
    Yoshimasa Saito
    Akiko Maeshima
    Miho Maeda
    Chitose Ogawa
    International Journal of Hematology, 2019, 109 : 228 - 232
  • [27] BRAF- and MAP2K1-Negative Multisystem Langerhans Cell Histiocytosis in an Elderly Patient
    Kothari, Rohit
    Bhatnagar, Anuj
    Varghese, Jeenu
    Kishore, Karthi
    Chand, Satish
    Mitra, Debdeep
    John, Arun
    INDIAN JOURNAL OF DERMATOLOGY, 2023, 68 (01) : 98 - +
  • [28] Targeting MAP2K1 mutation with trametinib in a triple wild-type melanoma patient.
    Homicsko, Krisztian Gyuta
    Aedo, Veronica
    Missiaglia, Edoardo
    Bisig, Bettina
    Michielin, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis Further Characterizing the Genomic Landscape of LCH
    McGinnis, Lisa M.
    Nybakken, Grant
    Ma, Lisa
    Arber, Daniel A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (07) : 885 - 890
  • [30] Multi-system Langerhans cell histiocytosis (MS-LCH): Clinical resistance associated with class 3 MAP2K1 (MEK1) Mutation in adult patients
    Rosler, W.
    Angst, F.
    Balabanov, S.
    Buhler, M. M.
    Clarenbach, C.
    Erlic, Z.
    Honecker, F.
    Hullner, M.
    Lang, C.
    Manz, M. G.
    SWISS MEDICAL WEEKLY, 2022, 152 : 35S - 36S
12345